


# IRA THREATENS CURES FOR PEOPLE WITH HEART DISEASE



## Study Shows Government-Mandated Drug Pricing Policies Decimate Development of Heart Failure Drugs

A new study by research firm Vital Transformation estimates that there would be hundreds of lost therapies, including those for patients with heart failure, if Congress expands flawed government-mandated drug pricing policies.

### LOST THERAPIES



**70%** of all currently available medicines – treatments Americans rely on every day – would likely never have been created, including nearly a dozen treatments for cardiovascular and other conditions that contribute to heart failure and related health concerns.

### LOST INNOVATION



**237** fewer medicines will be FDA-approved over the next decade, especially in areas where we desperately need cures – like heart failure.

## "PILL PENALTY" THREATENS DEVELOPMENT OF HEART DISEASE TREATMENTS

The new IRA law discourages the development of medicines that come in pill or tablet form, often referred to as "small molecule medicines." Small molecules play a critical role in management and treatment of heart failure – with functions ranging from blood pressure regulation, cholesterol control, anti-clotting agents, ACE inhibitors, beta blockers, and inflammation and immune response.<sup>1</sup>

Heart disease is the leading cause of death among men, women, and most racial and ethnic groups in the U.S., according to the Centers for Disease Control and Prevention.<sup>2</sup> The IRA's authority to mandate prices on medical discoveries shortly after they're approved will harm the largest and most vulnerable patient populations.



Time Limit Between FDA Approval & Mandated Price

IRA




Small-molecule drugs  
**9 years**





Biologics  
**13 years**

WH BUDGET PROPOSAL & SENATE SMART PRICES ACT



All drugs  
**5 years**

# IRA THREATENS CURES FOR PEOPLE WITH HEART DISEASE



## IRA THREATENS FUTURE OF HEART DISEASE INNOVATION FOR UNDERSERVED COMMUNITIES


The IRA's drug price-setting program failed to account for the lifetime cost and health equity for those who suffer from cardiovascular issues. Overall, **health care services for heart disease patients annually cost more than \$200 million**—and Black, Hispanic, American Indian, Asian and other communities of color **disproportionately endure increased risk of diagnosis and deaths.**<sup>3</sup>

And yet – three drugs used to treat heart failure or related cardiology conditions were selected among the 10 drugs subject to the first round of Medicare price setting. If the IRA leads to just a few cuts to heart failure innovation, Vital Transformation's analysis shows **more than 5.8 million patients will be affected**, a bleak outlook for those most in need.

## WHAT THEY'RE SAYING ABOUT INVESTMENTS

"I do expect that we will cancel some programs, whether that is, you know, a full-on indication for an existing medicine or a new medicine." – **Giovanni Caforio, CEO of Bristol Myers Squibb**<sup>4</sup>

"Under the IRA ... we may not have been able to invest in researching and developing Entresto in these additional indications, depriving patients of a meaningful treatment advance." – **Novartis**<sup>5</sup>



## LEARN MORE

The new study issued by We Work For Health (WWFH) and Vital Transformation modeled the impacts on industry revenues, jobs and future research and development investments. For the full study, please visit [We Work For Health](#).

1. [Types of Heart Medication](#). American Heart Association.

2. [Heart Disease Facts](#). Centers for Disease Control and Prevention.

3. [Heart Disease Facts](#). Centers for Disease Control and Prevention.

4. Smyth, J. [Bristol Myers Squibb warns US price reforms will dent drug development](#). Financial Times. 2022 Nov 22.

5. [Novartis statement about Entresto® \(sacubitril/valsartan\) selection for Medicare Drug Price Negotiation Program](#). Novartis. 2023 Aug 29.